Thu.Jul 08, 2021

article thumbnail

Gene therapy for sickle cell disease: progress and competition

Bio Pharma Dive

Treatments from Bluebird bio and CRISPR Therapeutics have shown considerable promise and could soon be nearing regulatory review. A full pipeline is growing behind them.

article thumbnail

There is some really bad DTC on TV

World of DTC Marketing

SUMMARY: TV continues to be the dominant channel for DTC advertising. Some of the TV spots for drugs are horrible, and some products should even be on TV because of terrible fair balance. TV ads only drive awareness as the first step for online health seekers. More conversations are happening on social media, and pharma seems to be immune to the conversations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA revises labeling of Biogen's Alzheimer's drug to emphasize early treatment

Bio Pharma Dive

The approval of Aduhelm last month, already highly controversial, was made more so by the agency's decision to clear the drug for an exceptionally broad group of patients. New prescribing information more closely matches clinical testing.

Drugs 294
article thumbnail

In the News: June 2021 Regulatory and Development Updates

Camargo

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. Old Antidepressants Being Repurposed to Treat Cancer . At Camargo, we have worked with hundreds of investigators who have found new targets for established drugs. It is exciting to find new uses of drugs with known safety because these drugs can reach new groups of patients in a relatively short timeframe.

article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Biohaven beats expectations with fast sales of migraine drug

Bio Pharma Dive

Second quarter sales of Nurtec ODT, which recently became the first migraine drug cleared for acute and preventive treatment, were nearly twice what analysts on Wall Street had predicted.

Sales 164
article thumbnail

Regular monitoring may be only way to prevent large COVID-19 outbreaks in schools

Scienmag

New simulations suggest that waiting until a student tests positive is too late for prevention Credit: Paul Tupper (CC BY 4.0, [link] A new study examines factors that underlie COVID-19 outbreaks in schools and suggests that large outbreaks can only be prevented with regular monitoring of everyone in the school setting. Paul Tupper and Caroline […].

Allergies 132

More Trending

article thumbnail

FDA Head Calls for Inspector General Investigation of Aduhelm Approval

BioSpace

Acting commissioner of the U.S. FDA asked the independent Office of the Inspector General to investigate how the FDA and representatives of Biogen interacted prior to the FDA’s approval of the company’s Aduhelm (aducanumab) for Alzheimer’s disease.

109
109
article thumbnail

Medicenna takes on deadly brain cancer in clinical trial

Outsourcing Pharma

The immunotherapy firm is conducting a Phase III trial centered on an innovative approach to treating recurrent glioblastoma, an aggressive brain cancer.

article thumbnail

Kuano raises £1m to further develop AI drug discovery platform

Pharma Times

Company is aiming to transform the discovery of therapeutics focused on enzyme inhibition

article thumbnail

GSK cancer head Hoos exits, takes top role at biotech Scorpion

pharmaphorum

GlaxoSmithKline’s head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion Therapeutics. . Hoos is leaving GSK after nine years, a period that saw a complete revamp of the unit including the wholesale divestment of cancer drugs to Novartis in a $16 billion deal announced in 2014 – which completed as he took over the division.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Merck partners with Innervia on bioelectronic therapy development

Pharma Times

Collaboration will focus on the development of smart neurostimulators for the treatment of severe chronic diseases

article thumbnail

Noting Delta Variant, Pfizer/BioNTech Plan to Ask FDA for Booster Shot EUA

BioSpace

The two companies said a booster dose given six months after the second dose had a consistent tolerability profile while still creating high immune responses against the Alpha and Beta variant.

article thumbnail

Study finds lower COVID-19 infection prevalence in fully vaccinated people

Pharma Times

COVID-19 infection rates were three times lower in fully vaccinated people compared to unvaccinated people

article thumbnail

WHO Calls on Roche and Regeneron to Lower Costs for Life-Saving COVID-19 Treatment

XTalks

The World Health Organization (WHO) has backed the use of interleukin (IL)-6 receptor blockers as a COVID-19 treatment for severely or critically ill patients with the infection, alongside corticosteroids. The IL-6 receptor antagonists are used to treat rheumatoid arthritis and include drugs such as Roche’s Actemra (tocilizumab) and Regeneron’s Kevzara (sarilumab).

Doctors 98
article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

Icequakes likely rumble along geyser-spitting fractures in Saturn’s icy moon Enceladus

Scienmag

Seismic activity could give scientists a read on the thickness of the ice encasing the moon and the oceans believed to lie beneath Credit: AGU/ JGR: Planets WASHINGTON–Tidal stresses may be causing constant icequakes on Saturn’s sixth largest moon Enceladus, a world of interest in the search for life beyond Earth, according to a new […].

article thumbnail

New patent expiration for Sucampo Pharma drug RESCULA

Drug Patent Watch

Annual Drug Patent Expirations for RESCULA Rescula is a drug marketed by Sucampo Pharma Llc and is included in one NDA. There is one patent protecting this drug and one…. The post New patent expiration for Sucampo Pharma drug RESCULA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98
article thumbnail

Climate changed the size of our bodies and, to some extent, our brains

Scienmag

Credit: Manuel Will The average body size of humans has fluctuated significantly over the last million years and is strongly linked to temperature. Colder, harsher climates drove the evolution of larger body sizes, while warmer climates led to smaller bodies. Brain size also changed dramatically but did not evolve in tandem with body size. An […].

98
article thumbnail

Chicago Biopharma Builds Commercial Facility in China to Focus on Antibody Development

BioSpace

?Sparx Therapeutics is expanding its operations into Yangzhou, China, with the imminent construction of a 1.2 million square foot facility for its commercial production.

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

Biomaterial vaccines ward off broad range of bacterial infections and septic shock

Scienmag

A new vaccine technology combining capture of bacterial pathogens with effective immune-reprogramming biomaterials could be applied to a broad spectrum of infectious diseases Credit: Wyss Institute at Harvard University. (BOSTON) — Current clinical interventions for infectious diseases are facing increasing challenges due to the ever-rising number of drug-resistant microbial infections, epidemic outbreaks of pathogenic bacteria, […].

article thumbnail

AZ, Amgen’s asthma med tezepelumab gains FDA priority review

Pharma Times

Priority review comes following positive results from the Phase III NAVIGATOR trial

Trials 134
article thumbnail

Red Dead Redemption 2 teaches players about wildlife

Scienmag

Credit: Matthew Silk Players of the popular game Red Dead Redemption 2 learn how to identify real American wildlife, new research shows. The game, set in the American West in 1899, features simulations of about 200 real species of animals. The new study, by the University of Exeter and Truro and Penwith College, challenged gamers […].

article thumbnail

Citing the Delta Variant, Pfizer Will Pursue Booster Shots and a New Vaccine

NY Times

Scientists were critical of the announcement, pointing to evidence that the current two-dose regimen is powerfully effective against the coronavirus.

article thumbnail

Accelerating Clinical Supply Through Integrated Drug Development

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

article thumbnail

Total-body PET imaging exceeds industry standards

Scienmag

Credit: Image created by Y. Abdelhafez and B.A. Spencer, EXPLORER Molecular Imaging Center, UC Davis, Sacramento, CA Reston, VA–A performance evaluation of the uEXPLORER total-body PET/CT scanner showed that it exhibits ultra-high sensitivity that supports excellent spatial resolution and image quality. Given the long axial field of view (AFOV) of the uEXPLORER, study authors have […].

article thumbnail

Philip Morris Makes $1.44 Billion Bid for UK Inhaled Drug Specialist Vectura Group

BioSpace

Philip Morris will acquire Vectura to gain access to its inhaled drug formulas to bolster its Beyond Nicotine strategy.

Drugs 111
article thumbnail

Passing the ball: Shifting responsibility for care coordination from patient to provider

Scienmag

Study finds HIE event notification promising tool to solve major healthcare challenge Credit: Regenstrief Institute INDIANAPOLIS – A new study from U.S. Department of Veterans Affairs, Regenstrief Institute, IUPUI and Icahn School of Medicine at Mount Sinai researchers reports that primary care physicians recognize the need for better coordination and welcome health information exchange (HIE) […].

article thumbnail

Muna Therapeutics Raises $73 Million to Advance Neurodegenerative Disease Focus

BioSpace

The company launches with the new funding to advance its focus on first-in-class small molecule therapies for neurodegenerative diseases.

98
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

To predict underwater volcano eruptions, scientist looks at images from space

Scienmag

A new study monitored satellite images to obtain sea discoloration data as a novel indicator in detecting if an underwater volcano’s eruption is imminent. Credit: JAXA/Yuji Sakuno A new study suggests sea discoloration data obtained from satellite images as a novel criterion in predicting if eruption looms for an underwater volcano. There have been frequent […].

article thumbnail

Ovid Realigns C-Suite After Throwing in the Towel on Phase III Candidate

BioSpace

This week's announcement includes a step to the side for CMO Amit Rakhit, who will transition to the biotech's advisory board.

98
article thumbnail

Ancient ostrich eggshell reveals new evidence of extreme climate change thousands of years ago

Scienmag

Credit: Philip Kiberd Evidence from an ancient eggshell has revealed important new information about the extreme climate change faced by human early ancestors. The research shows parts of the interior of South Africa that today are dry and sparsely populated, were once wetland and grassland 250,000 to 350,000 years ago, at a key time in […].

article thumbnail

Research Roundup: Clues to the Mystery of Fibromyalgia and More

BioSpace

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Research 101
article thumbnail

The New Clinical Trial Supply Chain: Resilient, Flexible, and Patient-Centric

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.